Listar por tema "Docetaxel"
Mostrando ítems 1-4 de 4
-
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
(Taylor & Francis, 2014-07-07)[Abstract] BACKGROUND: Based on the TROPIC study results, cabazitaxel was approved for the management of metastatic castration-resistant prostate cancer (mCRPC) progressing on or after docetaxel. METHODS: This multi-centre ... -
Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor
(Elsevier, 2015-03)[Abstract] Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer ... -
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
(American Association for Cancer Research, 2014-02-17)[Abstract] PURPOSE: Figitumumab is a human IgG2 monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R), with antitumor activity in prostate cancer. This phase II trial randomized chemotherapy-naïve ... -
Role of taxanes in advanced prostate cancer
(Springer, 2016-02-08)[Abstract] Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence ...